NASDAQ:NDRA ENDRA Life Sciences (NDRA) Stock Price, News & Analysis $5.74 +0.08 (+1.41%) Closing price 03:46 PM EasternExtended Trading$5.91 +0.17 (+2.96%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ENDRA Life Sciences Stock (NASDAQ:NDRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ENDRA Life Sciences alerts:Sign Up Key Stats Today's Range$5.71▼$6.0150-Day Range$3.26▼$6.4052-Week Range$2.90▼$11.96Volume13,261 shsAverage Volume80,802 shsMarket Capitalization$7.12 millionP/E RatioN/ADividend YieldN/APrice Target$30.00Consensus RatingHold Company Overview ENDRA Life Sciences, Inc. (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies. ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems. Using patented algorithms and specialized hardware, the system captures thermoacoustic signals generated when tissue is exposed to low-power microwave pulses. These signals enable clinicians to visualize temperature distributions during procedures such as radiofrequency ablation, microwave ablation and high-intensity focused ultrasound. The company collaborates with hospitals, academic research centers and medical device partners to conduct preclinical and clinical studies that validate the performance and utility of TAEUS technology. The company holds a growing portfolio of issued and pending patents across the United States, Europe and Asia, and it is advancing toward broader regulatory clearances and international market entry. ENDRA’s leadership team is led by President and Chief Executive Officer David Kaiss, who brings two decades of experience in medical device development, regulatory affairs and commercialization. Under his direction, the company has expanded its R&D capabilities, strengthened manufacturing partnerships and established key distribution channels to support future product launches.AI Generated. May Contain Errors. Read More ENDRA Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreNDRA MarketRank™: ENDRA Life Sciences scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingENDRA Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialENDRA Life Sciences has a consensus price target of $30.00, representing about 422.6% upside from its current price of $5.74.Amount of Analyst CoverageENDRA Life Sciences has only been the subject of 1 research reports in the past 90 days.Read more about ENDRA Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ENDRA Life Sciences are expected to grow in the coming year, from ($4.65) to ($4.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ENDRA Life Sciences is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ENDRA Life Sciences is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioENDRA Life Sciences has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ENDRA Life Sciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.31% of the float of ENDRA Life Sciences has been sold short.Short Interest Ratio / Days to CoverENDRA Life Sciences has a short interest ratio ("days to cover") of 1.72, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ENDRA Life Sciences has recently decreased by 23.46%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldENDRA Life Sciences does not currently pay a dividend.Dividend GrowthENDRA Life Sciences does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.63 News SentimentENDRA Life Sciences has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for ENDRA Life Sciences this week, compared to 1 article on an average week.MarketBeat Follows3 people have added ENDRA Life Sciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ENDRA Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders10.00% of the stock of ENDRA Life Sciences is held by insiders.Percentage Held by Institutions1.19% of the stock of ENDRA Life Sciences is held by institutions.Read more about ENDRA Life Sciences' insider trading history. Receive NDRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ENDRA Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NDRA Stock News HeadlinesENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility1 hour ago | finance.yahoo.comENDRA Life Sciences (NDRA) Projected to Post Earnings on ThursdayMay 14 at 2:09 AM | americanbankingnews.comFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.May 14 at 1:00 AM | Porter & Company (Ad)ENDRA Life Sciences (NDRA) price target decreased by 10.00% to 27.54April 15, 2026 | msn.comENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 31, 2026 | businesswire.comENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder ValueMarch 25, 2026 | finance.yahoo.comENDRA reports favourable data from Taeus Liver device study in MASLDFebruary 27, 2026 | yahoo.comENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient CareFebruary 26, 2026 | finance.yahoo.comSee More Headlines NDRA Stock Analysis - Frequently Asked Questions How have NDRA shares performed this year? ENDRA Life Sciences' stock was trading at $4.53 on January 1st, 2026. Since then, NDRA stock has increased by 26.7% and is now trading at $5.74. How were ENDRA Life Sciences' earnings last quarter? ENDRA Life Sciences Inc. (NASDAQ:NDRA) posted its earnings results on Friday, November, 14th. The company reported ($1.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.95) by $0.20. When did ENDRA Life Sciences' stock split? ENDRA Life Sciences's stock reverse split on Tuesday, August 20th 2024.The 1-50 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 19th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did ENDRA Life Sciences IPO? ENDRA Life Sciences (NDRA) raised $10 million in an initial public offering on Friday, February 3rd 2017. The company issued 2,000,000 shares at $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities acted as the underwriters for the IPO. How do I buy shares of ENDRA Life Sciences? Shares of NDRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ENDRA Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that ENDRA Life Sciences investors own include Bionano Genomics (BNGO), Cocrystal Pharma (COCP), AMC Entertainment (AMC), Plug Power (PLUG), Mustang Bio (MBIO), SNDL (SNDL) and BIOLASE (BIOL). Company Calendar Last Earnings11/14/2025Today5/14/2026Next Earnings (Estimated)5/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 NDRA's financial health is in the Green zone, according to TradeSmith. NDRA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:NDRA CIK1681682 Webwww.endrainc.com Phone(734) 335-0468FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for ENDRA Life Sciences$30.00 High Price Target$30.00 Low Price Target$30.00 Potential Upside/Downside+422.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($8.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.03 million Net MarginsN/A Pretax MarginN/A Return on Equity-397.71% Return on Assets-190.73% Debt Debt-to-Equity RatioN/A Current Ratio1.29 Quick Ratio1.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.92 per share Price / Book2.99Miscellaneous Outstanding Shares1,241,000Free Float1,117,000Market Cap$7.12 million OptionableNot Optionable Beta-0.11 Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:NDRA) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredPeptide Company Lands Exclusive MMA Wellness PartnershipA publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...The Tomorrow Investor | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredBlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...Awesomely, LLC | SponsoredDistracted Americans set to miss out on quadrillionsTechnology expert and Washington D.C. insider Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - s...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ENDRA Life Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ENDRA Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
